Bleakley Financial Group’s BeOne Medicines Ltd ONC Stock Holding History

Bleakley Financial Group’s Portfolio ONC Stock Details ONC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-3,976	Closed	-$734K	–	1051
2024 Q4	$734K	Sell	3,976 -55	-1%	-$11.2K	0.02%	501
2024 Q3	$905K	Sell	4,031 -1,508	-27%	-$271K	0.03%	425
2024 Q2	$790K	Sell	5,539 -122	-2%	-$18.8K	0.02%	475
2024 Q1	$885K	Buy	5,661 +1,942	+52%	+$313K	0.03%	459
2023 Q4	$671K	Sell	3,719 -109	-3%	-$19.7K	0.02%	507
2023 Q3	$689K	Buy	3,828 +55	+1%	+$10.9K	0.02%	473
2023 Q2	$673K	Sell	3,773 -840	-18%	-$193K	0.02%	511
2023 Q1	$994K	Buy	4,613 +931	+25%	+$223K	0.03%	386
2022 Q4	$810K	Buy	+3,682	New	+$675K	0.03%	421

Other funds holding ONC

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Bleakley Financial Group's ONC Position: Q1 2025 in Review

Bleakley Financial Group sold out of BeOne Medicines Ltd (ONC) in Q1 2025, closing a stake of 3,976 shares — an estimated $734K sold.

Bleakley Financial Group first reported a position in ONC in Q4 2022 and held it in 9 quarters. The position peaked at $994K in Q1 2023. 268 funds tracked by Wall St. Rank hold ONC as of Q1 2025.

Bleakley Financial Group reported no remaining BeOne Medicines Ltd position as of Q1 2025 after selling out during the quarter.
Bleakley Financial Group sold 3,976 BeOne Medicines Ltd shares in Q1 2025, an estimated $734K.
Bleakley Financial Group first reported a position in BeOne Medicines Ltd in Q4 2022 and held it in 9 quarters.
Bleakley Financial Group's BeOne Medicines Ltd position peaked at $994K in Q1 2023.
268 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q1 2025.

Based on Bleakley Financial Group's 13F filing for Q1 2025, filed 1 May 2025.